Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $8.8 Billion

Vertex Pharmaceuticals Incorporated (VRTX) entered a merger agreement on July 6, 2026, to acquire Crinetics Pharmaceuticals, Inc. (CRNX) in a deal valued at $8.8 billion.

Deal Structure:

Vertex will acquire all outstanding shares of Crinetics common stock for $85 per share in cash, representing a 102.24% premium on the stock’s last close.

Company Profile:

Crinetics is a clinical-stage pharmaceutical company that develops and commercializes small-molecule therapies for endocrine disorders and related tumors. Its portfolio includes the marketed acromegaly drug PALSONIFY (paltusotine) and a pipeline of investigational therapies targeting rare endocrine diseases and neuroendocrine tumors.

Vertex is a biotechnology company that develops and commercializes medicines for serious diseases, with marketed therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. The company also has a clinical pipeline focused on kidney diseases, type 1 diabetes, pain, neuromuscular disorders, and other serious conditions.

Deal Details and Timeline:

The deal is anticipated to close in the third quarter of 2026.

Crinetics’ medicine, PALSONIFY, was approved by the U.S. FDA in September 2025. It has also recently been approved in Europe and is currently being reviewed by regulators in other countries.

PALSONIFY is the first once-daily oral treatment for adults with acromegaly, a rare disease caused by a pituitary tumor that produces too much growth hormone. About 20,000 people in the U.S. have been diagnosed with this condition. The medicine helps patients quickly control the disease and bring important hormone levels back to normal.

Crinetics’ most advanced drug candidate, atumelnant, is a once-daily oral medicine that is currently in Phase 3 clinical trials for congenital adrenal hyperplasia (CAH). Classic CAH is the most severe form of the disease and affects about 17,000 treatable patients in the U.S.

It is a rare genetic disorder that prevents the adrenal glands from producing enough cortisol and often causes the body to make too much androgen. In Phase 2 clinical trials, atumelnant helped reduce excess androgen levels to near-normal while allowing patients to stay on normal replacement doses of glucocorticoids.

So far, atumelnant has been generally well tolerated, with no treatment-related severe or serious side effects reported.

The acquisition is expected to support Vertex’s revenue growth through the ongoing launch of PALSONIFY, which has blockbuster potential in the acromegaly market. Over the longer term, atumelnant could become a multi-billion-dollar product for CAH, with additional growth potential if approved for Cushing’s syndrome.

PALSONIFY and atumelnant together are expected to generate more than $5 billion in annual revenue. The acquisition is also expected to become accretive to Vertex’s non-GAAP operating income by 2029.

Vertex plans to fund the acquisition through a combination of cash on hand and debt. The company has secured $4.5 billion in fully committed bridge financing from Bank of America and Morgan Stanley Senior Funding.

Crinetics was advised by J.P. Morgan Securities and Leerink Partners on the financial aspects of the deal. Its legal advisors were Paul, Weiss, Rifkind, Wharton & Garrison and Morrison Foerster. Vertex received financial advice from Morgan Stanley and Lazard, while Kirkland & Ellis served as its legal advisor.

Deal Metrics:

For a comprehensive understanding of the metrics involved in this M&A transaction, please visit the Deal Metrics page at this link:

Deal Metrics for the acquisition of Crinetics Pharmaceuticals, Inc. (CRNX) by Vertex Pharmaceuticals Incorporated (VRTX)

The Deal Metrics page for each merger or acquisition includes:

• A historical spread chart of the merger from announcement through to completion or failure.
• Updates on every event as the merger progresses through stages such as the expiration of the HSR period, various regulatory approvals, shareholder votes, etc.
• Latest news and SEC filings.
• A record of deal updates.
• And much more.

Disclaimer: Please ensure to conduct your own due diligence before buying or selling any securities mentioned in this article. We do not guarantee the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article